Global consulting firm Capgemini has created the Pharmaceutical RFID (radio frequency identification) Center of Excellence to help pharmaceutical companies pilot drug pedigree authentication programs and reduce counterfeit drugs. Counterfeit drugs cost the pharmaceutical industry between $50 million and $100 million annually per company, Capgemini estimates. Capgemini teams with software vendor SupplyScape Corp. for this endeavor. The center is located in Cambridge, Mass. Capgemini says the joint initiative is designed to deliver an open, secure development environment to test anti-counterfeiting RFID pilots. Alternatively, clients can port the technology to their own locations to work on individual business issues. "Counterfeit drugs don't just create a patient safety issue, they are also a serious business problem," says Paul Nannetti, Capgemini global life sciences leader. "By maximizing brand security within the proposed FDA timeline, the pharmaceutical industry can meet its obligations and achieve significant return on investment, as well as improvements in efficiency and accuracy."